Abstract: A catheter system with two lumens (e.g., a major lumen and a minor lumen) that can be inserted peripherally into the left heart. The major lumen is used for venting, or blood volume removal, and the minor lumen is used to deliver a treatment substance directly to the left heart. In particular, the minor lumen can be used to deliver an anticoagulation medication directly to the left ventricle. The major lumen can be incorporated into an ECMO system.

Abstract: The present invention relates to methods of administering therapeutic agents to a donor organ prior to transplant comprising circulating the therapeutic agent through the donor organ while maintaining the donor organ under ex vivo perfusion conditions, as well as methods of transplanting organs, biologically modifying a donor organ prior to transplant, and treating organ failure using the methods disclosed herein.

Abstract: The present disclosure provides biomarkers useful for determining the risk of, prognosis of, and/or diagnosis of conditions such as ischemic and/or non-ischemic heart failure in a subject.

Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (?-AR). ?-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a ?-AR transgene, a ?-ARK transgene, or a ?-ARK inhibitor transgene.

Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (&bgr;-AR). &bgr;-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a &bgr;-AR transgene, a &bgr;-ARK transgene, or a &bgr;-ARK inhibitor transgene.

Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (&bgr;-AR). &bgr;-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a &bgr;-AR transgene, a &bgr;-ARK transgene, or a &bgr;-ARK inhibitor transgene.